Transmarket Holdings’s Novartis NVS Stock Holding History

Transmarket Holdings’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,075	Closed	-$5.36M	–	54
2026 Q1	$5.36M	Buy	35,075 +32,847	+1,474%	+$5.04M	2.86%	7
2025 Q4	$307K	Buy	+2,228	New	+$292K	0.22%	35

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Natixis Advisors Boston, Massachusetts $88.9B AUM 38.03% 1-Year Est. Return

Transmarket Holdings's NVS Position: Q2 2026 in Review

Transmarket Holdings sold out of Novartis (NVS) in Q2 2026, closing a stake of 35,075 shares — an estimated $5.36M sold.

Transmarket Holdings first reported a position in NVS in Q4 2025 and held it in 2 quarters. The position peaked at $5.36M in Q1 2026. 1,546 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Transmarket Holdings reported no remaining Novartis position as of Q2 2026 after selling out during the quarter.
Transmarket Holdings sold 35,075 Novartis shares in Q2 2026, an estimated $5.36M.
Transmarket Holdings first reported a position in Novartis in Q4 2025 and held it in 2 quarters.
Transmarket Holdings's Novartis position peaked at $5.36M in Q1 2026.
1,546 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Transmarket Holdings's 13F filing for Q2 2026, filed 21 Jul 2026.